Rapid, sensitive and cost-effective determination of immune checkpoint inhibitor activity using a magnetic bead-based binding assay

J Immunol Methods. 2021 Nov:498:113134. doi: 10.1016/j.jim.2021.113134. Epub 2021 Aug 28.

Abstract

Immune checkpoint Inhibitors (ICIs) are effective immunno-therapeutic agents for cancer. Rapid and sensitive determination of the blocking activity of ICIs is important for ICIs development and immunological research. Among various immune checkpoint (IC) binding assays, cell-based binding assays are widely regarded, and the functional ELISA is a convenient alternative. However, these methodologies are limited by time-consuming preparation of cell lines stably expressing IC molecules, or long turnaround time with high cost. In this study, two magnetic bead based binding assays were developed to evaluate activity of ICIs, which was determined by a soluble ligand/bead immobilized receptor based binding assay (sL/bR binding assay) that assessed efficacy to block binding of one soluble IC ligand on its cognate receptor immobilized beads, or by a soluble receptor/bead immobilized ligand based binding assay (sR/bL binding assay) that assessed efficacy to block binding of soluble IC receptor on its cognate ligand immobilized beads. Half maximal inhibitory concentration (IC50) values of ICIs were calculated to determine ICIs activity. The sL/bR binding assay accurately determined the activity of two TIGIT blocking antibodies, since the relative blocking activity of two TIGIT antibodies determined by the sL/bR binding assay established in this study and that by the cell based binding assay were almost identical. In contrast, the sR/bL binding assay showed significantly improved sensitivity to determine activity of two PD-1 blocking antibodies than the sL/bR binding assay that was tested in this study and previous reports. Moreover, both amount of the used recombinant protein of ICI receptor/ligand and turnaround time of the two binding assays were more than 10 times less than those of the functional ELISA. These data indicate that the two magnetic bead based binding assays are sensitive, rapid and cost-effective methods to determine blocking activity of ICIs.

Keywords: Immune checkpoint binding assay; Immune checkpoint inhibitor; Magnetic bead; Nivolumab; PD-1; TIGIT.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / immunology
  • Antibody Specificity
  • CHO Cells
  • Cell Line, Tumor
  • Cost Savings
  • Cost-Benefit Analysis
  • Cricetulus
  • Enzyme-Linked Immunosorbent Assay / economics
  • Flow Cytometry / economics
  • HEK293 Cells
  • Humans
  • Immune Checkpoint Inhibitors / pharmacology*
  • Immunoassay / economics*
  • Mice
  • Nivolumab / pharmacology*
  • Predictive Value of Tests
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors*
  • Programmed Cell Death 1 Receptor / immunology
  • Programmed Cell Death 1 Receptor / metabolism
  • Receptors, Immunologic / antagonists & inhibitors*
  • Receptors, Immunologic / immunology
  • Receptors, Immunologic / metabolism
  • Reproducibility of Results
  • Time Factors
  • Workflow

Substances

  • Antibodies, Monoclonal
  • Immune Checkpoint Inhibitors
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Receptors, Immunologic
  • TIGIT protein, human
  • Nivolumab